文献速递流行病学与生物统计医学教育与科研方法

患者与公众参与试验数值环节(PoINT):经验与优先事项

Patient and public involvement in numerical aspects of trials (PoINT): exploring patient and public partners experiences and identifying stakeholder priorities.
PubMed 文献 · Trials · 2021-07-28

本研究通过在线焦点小组(9名患者与公众伙伴)和基于James Lind Alliance方法的在线优先事项设定会议(14名英国和爱尔兰利益相关者),探讨患者与公众参与试验数值环节的经验与意见,并确定优先领域。焦点小组识别出四个主题;优先事项会议从十二个数值方面中选出目标差异、结果解释和成本效果三个优先方面。

要点

  • 患者与公众伙伴认为参与研究数值环节重要,但沟通需更清晰。
  • 其角色被视为提供外部视角,主要关注假设和定量研究传播。
  • 优先数值方面为:目标差异、结果解释和成本效果。

核心结论

  • 患者与公众参与试验数值环节重要,应通过清晰沟通和建立信任关系来促进。
  • 优先的数值方面包括目标差异、结果解释和成本效果。

研究设计与样本

  • 两阶段研究:第一阶段在线焦点小组,第二阶段在线优先事项设定会议。
  • 焦点小组纳入9名患者与公众伙伴;优先事项会议纳入14名英国和爱尔兰利益相关者。

主要发现

  • 焦点小组分析识别出四个主题:数值方面PPI的决定因素、身份与角色、参与数值方面的影响。
  • 患者与公众伙伴认为参与数值方面重要且应被促进,但沟通需更清晰。
  • 患者与公众伙伴主要关注假设和定量研究传播的参与。
  • 优先事项会议从十二个数值方面中选出三个优先方面:目标差异、结果解释和成本效果。

关键数值与推荐

  • 优先事项设定会议采用James Lind Alliance方法,基于投票系统讨论和排序。
  • 优先数值方面:目标差异、结果解释和成本效果。

临床怎么用

  • 在试验数值讨论中纳入患者与公众伙伴,提供讨论时间、知识支持和清晰语言。
  • 优先关注目标差异、结果解释和成本效果方面的参与。

局限性

  • 焦点小组样本量小(n=9),优先事项会议参与者14名,可能限制普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patient and public involvement is increasingly common in trials, but its quality remains variable in a lot of settings. Many key decisions in trials involve numbers, but patients are rarely involved in those discussions. We aimed to understand patient and public partners' experiences and opinions regarding their involvement in numerical aspects of research and discuss and identify priorities, according to multiple stakeholders, around the most important numerical aspects in trials to involve patients and the public in. METHODS: The study had two stages: (1) online focus groups with patient and public partners recruited via online platforms and analysed using inductive thematic analysis and (2) online priority setting meeting with UK- and Ireland-based stakeholders and following James Lind Alliance methodology. Pre-selected numerical aspects were introduced prior to the meeting and discussed and prioritised based on a voting system. RESULTS: In stage 1, we held two focus groups with patient and public partners (n = 9). We identified four themes in the analysis: "Determinants of PPI in numerical aspects", "Identity and roles", "Impact of involving patients and the public in numerical aspects". Patient and public partners believed being involved in numerical aspects of research is important and should be facilitated, but communication about these aspects needs to be clearer. An environment and relationship with researchers that facilitates that will include time for discussion, support to improve knowledge and confidence, clear language and definitions and trust. Patient and public partners perceive their role as bringing an outsider perspective and were mainly interested in involvement in assumptions and dissemination of quantitative research. They believed this can lead to more transparency and improve their experience by making involvement more meaningful. In stage 2, we identified twelve numerical aspects of trials to be prioritised. We held a priority setting meeting with 14 stakeholders, which led to the selection of three priority numerical aspects in patient and public involvement: target differences, interpretation of results and cost-effectiveness. Participants felt all aspects should be considered for involvement and their communication needs to ensure a shared level of understanding to avoid power imbalances. CONCLUSIONS: Our work shows the importance of involving patient and public partners in numerical aspects of trials by assessing their experiences and motivations for the first time and discussing and prioritising which numerical aspects of trials are the most important for patients and the public to contribute to. Our research provides a platform for future efforts to improve patient and public involvement in trials and a prioritised set of future research foci.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Goulao B, Bruhn H, Campbell M, et al. Patient and public involvement in numerical aspects of trials (PoINT): exploring patient and public partners experiences and identifying stakeholder priorities. Trials. 2021. PMID: 34321066. doi:10.1186/s13063-021-05451-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。